US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist
  • 681.580
  • -11.650-1.68%
Close Jan 17 16:00 ET
  • 681.580
  • 0.0000.00%
Post 20:01 ET
74.90BMarket Cap16.86P/E (TTM)

Regeneron Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Regeneron Pharmaceuticals Q4 2024 Estimates Date

Currency：USDFeb 4, 2025

Estimate YoY
Revenue
3.76B
+9.49%
EPS
8.64
-15.23%
Analyst Rating
Buy

Jan 17, 2025

Regeneron Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 9 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 3.543B--
Feb 4, 20252024/Q4-- / 3.760B--
Oct 31, 20242024/Q33.721B / 3.667B--
Aug 1, 20242024/Q23.547B / 3.387B--
May 2, 20242024/Q13.145B / 3.221B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 3.543B--
Feb 4, 20252024/Q4-- / 3.760B--
Oct 31, 20242024/Q33.721B / 3.667B--
Aug 1, 20242024/Q23.547B / 3.387B--
May 2, 20242024/Q13.145B / 3.221B--

Unlock Free Earnings Estimates

Regeneron Pharmaceuticals Earnings Reports

  • Regeneron Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

    Oct 31, 2024 07:21 ET

  • Regeneron Pharmaceuticals | 8-K: Regeneron Reports Third Quarter 2024 Financial and Operating Results

    Oct 31, 2024 07:15 ET

  • Regeneron Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

    Aug 1, 2024 07:21 ET

  • Regeneron Pharmaceuticals | 8-K: Regeneron Reports Second Quarter 2024 Financial and Operating Results

    Aug 1, 2024 07:11 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jan 17, 2025

    Buy

    • Buy

      72.00%

    • Hold

      20.00%

    • Sell

      8.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data

    Investment Theme Infectious Disease
    Infectious Disease
    Intraday-0.73%